Table 2 Cytokine therapy clinical trials for oral cancers
From: Tumor microenvironment and immunotherapy of oral cancer
Cytokines | Sponsor | Country | Estimated date of completion | Phase | Status | Identifier |
|---|---|---|---|---|---|---|
IL-12 | NYU Langone Health | United States | May 2009 | Â | Completed | NCT00899821 |
IL-12 or GM-CSF | National Cancer Institute (NCI) | United States | May 2007 | II | Completed | NCT00019331 |
PEG-IFN-α-2b | M.D. Anderson Cancer Center | United States | March 2006 | II | Completed | NCT00276523 |
IL-2 gene | H. Lee Moffitt Cancer Center and Research Institute | United States | June 2004 | II | Completed | NCT00006033 |
IFN-α | Eastern Cooperative Oncology Group | United States | May 2009 | III | Completed | NCT00054561 |
IFN-α | Hoag Memorial Hospital Presbyterian | United States | February 1999 | II | Completed | NCT00002506 |
Salivary cytokines | University Hospital, Basel, Switzerland | Switzerland | January 202 | Â | Completed | NCT02807519 |
PEG-IFN-α-2b | Dartmouth-Hitchcock Medical Center | United States | November 2002 | I | Completed | NCT00014261 |